Skip to main content
    F

    Foghorn Therapeutics Inc (FHTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.79
    -0.28 (-13.53%)

    Market Cap: $124.12M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Foghorn Therapeutics Inc (FHTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Foghorn Therapeutics reported revenue of $30.91M for the fiscal year ended Dec 31, 2025, up 36.8% from the year before. That year, net income was -$74.28M with a net margin of -240.3%, operating cash flow was -$86.10M and free cash flow was -$86.15M. The quarter ended Sep 30, 2026 had revenue of $83.54M and net income of $58.15M.

    Revenue and Margins

    Over the 5 years to Dec 2025, revenue grew from $430.00K, a compound annual rate of 135.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$30.91M+36.8%100.0%-279.5%-240.3%
    Dec 2024$22.60M-33.8%100.0%-454.3%-383.2%
    Dec 2023$34.16M+77.6%100.0%-315.9%-288.2%
    Dec 2022$19.23M+1357.8%100.0%-609.2%-566.3%
    Dec 2021$1.32M+206.7%100.0%-7637.1%-7681.6%
    Dec 2020$430.00KN/A100.0%-15937.4%-16000.0%
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$30.91M$22.60M$34.16M$19.23M$1.32M$430.00K$0$0
    Cost of revenue$0$0$0$0$0$0$0$379.00K
    Gross profit$30.91M$22.60M$34.16M$19.23M$1.32M$430.00K$0-$379.00K
    Research and development$85.47M$94.53M$109.69M$105.62M$80.33M$57.72M$44.36M$21.23M
    Operating income-$86.39M-$102.68M-$107.91M-$117.14M-$100.73M-$68.53M-$51.08M-$26.05M
    Net income-$74.28M-$86.62M-$98.43M-$108.88M-$101.32M-$68.80M-$51.13M-$26.34M
    EBITDA-$81.62M-$100.01M-$104.28M-$112.53M-$94.83M-$66.27M-$49.90M-$25.59M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$83.54M$16.07M$3.27M$9.25M$8.15M$7.56M$5.95M$2.86M$7.81M$6.89M$5.05M$5.77M
    Gross profit$83.54M$16.07M$3.27M$9.25M$8.15M$7.56M$5.95M$2.86M$7.81M$6.89M$5.05M$5.77M
    Operating income$56.64M-$8.80M-$21.57M-$23.88M-$18.50M-$21.10M-$22.91M-$24.00M-$23.85M-$26.63M-$28.19M-$25.46M
    Net income$58.15M-$7.19M-$19.88M-$21.66M-$15.85M-$17.94M-$18.83M-$19.50M-$19.12M-$22.98M-$25.02M-$24.11M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $923.00K by $79.95M. Shareholder equity was negative, at -$108.50M, as total liabilities of $306.60M exceeded total assets of $198.10M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$198.10M$283.98M$285.92M$404.88M$519.77M$255.59M$22.34M$43.06M
    Current assets$163.24M$249.60M$240.18M$351.40M$459.56M$190.69M$16.89M$40.40M
    Cash and equivalents$80.88M$55.45M$80.34M$52.21M$101.14M$92.80M$14.98M$40.02M
    Total liabilities$306.60M$329.51M$363.11M$404.77M$422.90M$109.41M$23.81M$82.33M
    Short-term debt$923.00K$9.07M$8.52M$5.97M$6.99M$3.98M$4.15MN/A
    Long-term debtN/AN/AN/AN/AN/A$19.65M$10.96M$7.03M
    Shareholder equity-$108.50M-$45.53M-$77.19M$112.00K$96.87M$146.19M-$88.02M-$39.27M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$190.95M$203.39M$222.17M$198.10M$204.96M$226.24M$258.69M$283.98M$308.37M$328.58M$255.00M$285.92M
    Total liabilities$205.04M$284.43M$298.57M$306.60M$294.62M$302.89M$320.34M$329.51M$336.66M$342.91M$352.49M$363.11M
    Cash and equivalents$80.30M$68.08M$87.66M$80.88M$89.33M$72.57M$61.03M$55.45M$57.68M$138.95M$79.25M$80.34M
    Shareholder equity-$14.08M-$81.04M-$76.41M-$108.50M-$89.66M-$76.66M-$61.65M-$45.53M-$28.29M-$14.32M-$97.49M-$77.19M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$86.10M-$100.41M-$118.11M$193.61M-$50.25M-$31.29M-$46.34M-$22.65M
    Capital expenditures$50.00K$906.00K$1.22M$1.21M$3.31M$16.18M$968.00K$1.54M
    Free cash flow-$86.15M-$101.31M-$119.33M$192.40M-$53.56M-$47.47M-$47.30M-$24.19M
    Share repurchases$0$585.00K$0N/AN/AN/AN/AN/A
    Investing cash flow$112.04M-$29.90M$144.45M-$244.32M$36.17M-$108.91M-$964.00K-$1.54M
    Financing cash flow$1.02M$105.43M$1.78M$1.76M$22.42M$217.47M$23.97M$51.77M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$18.24M-$17.84M-$25.27M-$22.27M-$18.86M-$21.00M-$23.97M-$24.52M-$21.00M-$25.54M-$29.34M-$27.54M
    Capital expenditures$7.00K$50.00K$0$0$0$22.00K$28.00K$479.00K$309.00K$17.00K$101.00K$37.00K
    Free cash flow-$18.25M-$17.89M-$25.27M-$22.27M-$18.86M-$21.02M-$24.00M-$25.00M-$21.31M-$25.55M-$29.45M-$27.58M
    Last 12 quarters

    Frequently Asked Questions About FHTX

    What is Foghorn Therapeutics' annual revenue?

    Foghorn Therapeutics reported revenue of $30.91M for the fiscal year ended Dec 31, 2025.

    How fast is Foghorn Therapeutics' revenue growing?

    Revenue was up 36.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 17.1%.

    Is Foghorn Therapeutics profitable?

    No. Foghorn Therapeutics reported net income of -$74.28M for the fiscal year ended Dec 31, 2025, with a net margin of -240.3%.

    How much free cash flow does FHTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$86.10M minus capital expenditures of $50.00K produced free cash flow of -$86.15M.

    How much debt does Foghorn Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $923.00K and cash and equivalents of $80.88M.